FDA Issues a Temporary Compounding Policy to Head Off a Shortage of Starter IV Nutrition for Newborns as Two Outsourcing Facilities Close

The FDA has moved to head off a shortage of one of the most fragile products in hospital medicine: the sterile intravenous nutrition that sustains premature and critically ill newborns in their first hours of life. In guidance published in the Federal Register on September 9, 2026, the agency said it will temporarily refrain from enforcing parts of the federal drug-compounding rules so that hospital pharmacies and outsourcing facilities can keep making 'starter' parenteral nutrition, after two outsourcing facilities that supply the standardized product told the FDA they are permanently closing.

What the FDA did

The guidance, 'Temporary Policies for Compounding Certain Starter Parenteral Nutrition Drug Products for Neonates,' was published in the Federal Register on September 9, 2026 (91 FR 57358) and took effect for immediate implementation, without the prior public comment period FDA guidance usually goes through. It sets out temporary enforcement priorities for how certain starter parenteral nutrition products for neonates may be compounded by state-licensed pharmacies, federal facilities, and registered outsourcing facilities. The FDA framed the step as a way to keep hospitals supplied while other sources increase production, with Acting Commissioner Kyle Diamantas saying the agency was deploying the regulatory tools available to prevent supply-chain gaps and the acting director of its drug center, Michael Davis, saying the goal was to help hospitals maintain access during the transition.

What starter parenteral nutrition is, and why it matters

Parenteral nutrition delivers nutrients directly into a vein when a patient cannot eat or absorb food through the gut. For the smallest newborns, that support often has to begin within hours of birth. 'Starter' formulations are standardized, ready-to-use mixtures (dextrose and amino acids with electrolytes) that a hospital can hang immediately while a fully individualized bag is prepared. The infants who need them, premature babies, critically ill newborns, and infants with surgical conditions of the gut, cannot be fed by mouth or feeding tube and cannot wait, which is why an interruption in supply is treated as an emergency rather than an inconvenience.

Why the supply is at risk

The FDA said the guidance was prompted by the expected market exit of the predominant U.S. source of certain standardized neonatal starter parenteral nutrition products. According to the agency, two outsourcing facilities that make the products are permanently shutting down. The FDA has not publicly named the two facilities or stated exactly when their production stops. The concern is not a current, confirmed outage but an anticipated gap the agency is trying to bridge before it reaches the bedside.

The temporary policy for hospital and state-licensed pharmacies

Under section 503A of the Federal Food, Drug, and Cosmetic Act, a state-licensed pharmacy generally compounds against a patient-specific prescription. The guidance loosens that requirement for a defined window. For 180 days, until March 8, 2027, the FDA says it does not intend to take action against a state-licensed pharmacy or a federal facility that is not registered as an outsourcing facility, including a hospital or health-system pharmacy, for providing a compounded starter parenteral nutrition product to a hospital or health system without first receiving a patient-specific prescription, provided the conditions in the guidance are met. Those conditions, per the FDA, include:

• The product is one of the starter parenteral nutrition drugs listed in the guidance's Appendix A.
• It is labeled with, and used within, the beyond-use dates set out in the guidance's Appendix B.
• It is single-use and does not contain antimicrobial preservatives.
• The relevant state pharmacy authority is aware of the compounding and does not object.
• The other applicable conditions of section 503A and the rest of the Food, Drug, and Cosmetic Act are met.

The temporary policy for outsourcing facilities

Registered outsourcing facilities, which operate under section 503B, can already compound without patient-specific prescriptions, but they must generally use bulk drug substances that appear on the FDA's 503B bulks list and must meet current good manufacturing practice requirements. The guidance eases two of those constraints for the same emergency purpose. The FDA says it does not intend to act on an outsourcing facility's use of certain bulk drug substances that are not on the 503B list under section 503B(a)(2)(A), or on the facility not meeting certain manufacturing requirements for product stability testing and for establishing an expiration date, when the circumstances described in the guidance are present.

What this changes, and what it does not

Enforcement discretion is a statement that the FDA does not intend to pursue action in defined situations. It is not a rule, and it does not repeal or rewrite the compounding statutes. The policy is time-limited, ending March 8, 2027, and conditional on the specific products, labeling, and safeguards the guidance lists. Like other FDA guidance, the document represents the agency's current thinking, is nonbinding on industry and on the FDA, and was published for immediate use but remains open to comment under the agency's good guidance practices. If conditions change, the FDA can revise or withdraw it.

Practical notes

This is general information, not medical or legal advice. The operative details for anyone acting on the policy, meaning the eligible products, the beyond-use dating, and the full list of conditions, live in the FDA guidance and its appendices, and state boards of pharmacy set additional requirements that the guidance does not displace. For clinicians, pharmacists, and hospital supply teams weighing whether to compound in-house or source from an outsourcing facility, a few starting points:

• Work from the FDA guidance text and its Appendix A and Appendix B rather than a news summary before compounding or distributing.
• Coordinate with the applicable state board of pharmacy, since the 503A pathway in the guidance turns on the state authority being aware and not objecting.
• Report suspected quality problems or adverse events to the FDA's MedWatch program.